Known targets — ChEMBL curated mechanism
GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQ
The experimentally established mechanism targets of Meclonazepam. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRP known ✓ | O00591 | 1/20 | 0.46 |
| ▸ | GABRD known ✓ | O14764 | 1/20 | 0.46 |
| ▸ | GABRA1 known ✓ | P14867 | 1/20 | 0.46 |
| ▸ | GABRB1 known ✓ | P18505 | 1/20 | 0.46 |
| ▸ | GABRG2 known ✓ | P18507 | 1/20 | 0.46 |
| ▸ | GABRB3 known ✓ | P28472 | 1/20 | 0.46 |
| ▸ | GABRA5 known ✓ | P31644 | 1/20 | 0.46 |
| ▸ | GABRA3 known ✓ | P34903 | 1/20 | 0.46 |
| ▸ | GABRA2 known ✓ | P47869 | 1/20 | 0.46 |
| ▸ | GABRB2 known ✓ | P47870 | 1/20 | 0.46 |
| ▸ | GABRA4 known ✓ | P48169 | 1/20 | 0.46 |
| ▸ | GABRE known ✓ | P78334 | 1/20 | 0.46 |
| ▸ | GABRA6 known ✓ | Q16445 | 1/20 | 0.46 |
| ▸ | GABRG1 known ✓ | Q8N1C3 | 1/20 | 0.46 |
| ▸ | GABRG3 known ✓ | Q99928 | 1/20 | 0.46 |
| ▸ | GABRQ known ✓ | Q9UN88 | 1/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.63 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.63 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.63 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Flunitrazepam SCHEMBL18316507 | 0.84 | GABRA1 (0.63) | OPRK1CHRM2ADRA2APDE4DLMNA | |
| Meclonazepam SCHEMBL2109365 | 0.83 | GABRA1 (0.63) | PDE4DLMNAPGRMEN1KMT2A | |
| SCHEMBL31365170 | 0.83 | LMNA (0.71) | PDE4DLMNAPGRMEN1ALB | |
| Meclonazepam SCHEMBL7269783 | 0.83 | GABRA1 (0.63) | PDE4DLMNAPGRMEN1KMT2A | |
| Meclonazepam SCHEMBL29365672 | 0.83 | GABRA1 (0.63) | PDE4DLMNAPGRMEN1KMT2A | |
| Clonazepam SCHEMBL16719271 | 0.83 | GABRA1 (0.61) | OPRK1CHRM2ADRA2APDE4DLMNA | |
| SCHEMBL11060309 | 0.81 | OPRK1 (0.55) | OPRK1CHRM2ADRA2APDE4DLMNA | |
| SCHEMBL11060317 | 0.81 | OPRK1 (0.55) | OPRK1CHRM2ADRA2APDE4DLMNA | |
| Clonazepam SCHEMBL5500649 | 0.80 | GABRA1 (0.74) | OPRK1PDE4DLMNAPGRMEN1 | |
| Lormetazepam SCHEMBL43267 | 0.79 | OPRK1 (1.00) | OPRK1CHRM2ADRA2APDE4DLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2593104-A2 | METHODS OF TREATING AND PREVENTING/REDUCING THE LIKELIHOOD OF MESIAL TEMPORAL LOBE EPILEPSY (TLE) | Müller, Prof. Dr., Wolfgang (DE) | 2013-05-22 | — | — | EP | disclosed |
| WO-2011011692-A2 | METHODS OF TREATING AND PREVENTING/REDUCING THE LIKELIHOOD OF MESIAL TEMPORAL LOBE EPILEPSY (TLE) | STC.UNM (US) | 2011-01-27 | — | — | WO | disclosed |